Active 0 6 0 6 O
second 7 13 7 13 O
malignancy 14 24 14 24 B-cancer
that 25 29 25 29 O
in 30 32 30 32 O
the 33 36 33 36 O
opinion 37 44 37 44 O
of 45 47 45 47 O
the 48 51 48 51 O
PI 52 54 52 54 O
may 55 58 55 58 O
interfere 59 68 59 68 O
with 69 73 69 73 O
or 74 76 74 76 O
be 77 79 77 79 O
adversely 80 89 80 89 O
affected 90 98 90 98 O
by 99 101 99 101 O
this 102 106 102 106 O
treatment 107 116 107 116 B-treatment

Acute 0 5 117 122 B-cancer
promyelocytic 6 19 123 136 I-cancer
leukemia 20 28 137 145 I-cancer
( 29 30 146 147 I-cancer
FAB 30 33 147 150 I-cancer
M3 34 36 151 153 I-cancer
AML 37 40 154 157 I-cancer
) 40 41 157 158 I-cancer

Adequate 0 8 159 167 O
liver 9 14 168 173 O
function 15 23 174 182 O
as 24 26 183 185 O
defined 27 34 186 193 O
by 35 37 194 196 O
total 38 43 197 202 B-clinical_variable
bilirubin 44 53 203 212 I-clinical_variable
≤ 54 55 213 214 O
2.0 56 59 215 218 B-upper_bound
mg 60 62 219 221 I-upper_bound
/ 62 63 221 222 I-upper_bound
dL 63 65 222 224 I-upper_bound
( 66 67 225 226 O
≤ 67 68 226 227 O
3.0 69 72 228 231 B-upper_bound
mg 73 75 232 234 I-upper_bound
/ 75 76 234 235 I-upper_bound
dL 76 78 235 237 I-upper_bound
for 79 82 238 241 O
patients 83 91 242 250 O
with 92 96 251 255 O
known 97 102 256 261 O
Gilbert 103 110 262 269 B-chronic_disease
's 110 112 269 271 I-chronic_disease
syndrome 113 121 272 280 I-chronic_disease
) 121 122 280 281 O
and 123 126 282 285 O
AST 127 130 286 289 B-clinical_variable
/ 130 131 289 290 O
ALT 131 134 290 293 B-clinical_variable
≤ 135 136 294 295 O
3 137 138 296 297 B-upper_bound
times 139 144 298 303 I-upper_bound
upper 145 150 304 309 I-upper_bound
limit 151 156 310 315 I-upper_bound
of 157 159 316 318 I-upper_bound
normal 160 166 319 325 I-upper_bound
, 166 167 325 326 O
unless 168 174 327 333 O
these 175 180 334 339 O
are 181 184 340 343 O
thought 185 192 344 351 O
to 193 195 352 354 O
be 196 198 355 357 O
due 199 202 358 361 O
to 203 205 362 364 O
AML 206 209 365 368 B-cancer

Adequate 0 8 369 377 O
renal 9 14 378 383 O
function 15 23 384 392 O
with 24 28 393 397 O
creatinine 29 39 398 408 B-clinical_variable
≤ 40 41 409 410 O
2.0 42 45 411 414 B-upper_bound
mg 46 48 415 417 I-upper_bound
/ 48 49 417 418 I-upper_bound
dL 49 51 418 420 I-upper_bound

Age 0 3 421 424 B-age
> 4 5 425 426 O
= 5 6 426 427 O
18 6 8 427 429 B-lower_bound

Allogeneic 0 10 430 440 B-treatment
or 11 13 441 443 O
autologous 14 24 444 454 B-treatment
transplant 25 35 455 465 I-treatment
for 36 39 466 469 O
AML 40 43 470 473 B-cancer
with 44 48 474 478 O
infusion 49 57 479 487 B-treatment
of 58 60 488 490 I-treatment
stem 61 65 491 495 I-treatment
cells 66 71 496 501 I-treatment
within 72 78 502 508 O
90 79 81 509 511 B-upper_bound
days 82 86 512 516 I-upper_bound
of 87 89 517 519 O
study 90 95 520 525 O
entry 96 101 526 531 O
or 102 104 532 534 O
on 105 107 535 537 O
active 108 114 538 544 O
immunosuppressive 115 132 545 562 B-treatment
therapy 133 140 563 570 I-treatment
for 141 144 571 574 O
( 145 146 575 576 O
GVHD 146 150 576 580 B-chronic_disease
) 150 151 580 581 O
within 152 158 582 588 O
2 159 160 589 590 B-upper_bound
weeks 161 166 591 596 I-upper_bound
before 167 173 597 603 I-upper_bound
study 174 179 604 609 O
entry 180 185 610 615 O

Chemotherapy 0 12 616 628 B-treatment
, 12 13 628 629 O
radiation 14 23 630 639 B-treatment
, 23 24 639 640 O
or 25 27 641 643 O
immunotherapy 28 41 644 657 B-treatment
, 41 42 657 658 O
within 43 49 659 665 O
2 50 51 666 667 B-upper_bound
weeks 52 57 668 673 I-upper_bound
prior 58 63 674 679 I-upper_bound
to 64 66 680 682 O
study 67 72 683 688 O
entry 73 78 689 694 O
, 78 79 694 695 O
other 80 85 696 701 O
than 86 90 702 706 O
those 91 96 707 712 O
specified 97 106 713 722 O
in 107 109 723 725 O
the 110 113 726 729 O
inclusion 114 123 730 739 O
criteria 124 132 740 748 O
( 133 134 749 750 O
hydroxyurea 134 145 750 761 B-treatment
and 146 149 762 765 O
hypomethylating 150 165 766 781 B-treatment
agents 166 172 782 788 I-treatment
) 172 173 788 789 O

Cytarabine 0 10 790 800 B-treatment
containing 11 21 801 811 O
regimen 22 29 812 819 O
in 30 32 820 822 O
excess 33 39 823 829 O
of 40 42 830 832 O
2 43 44 833 834 B-upper_bound
g 45 46 835 836 I-upper_bound
/ 46 47 836 837 I-upper_bound
m2 47 49 837 839 I-upper_bound
/ 49 50 839 840 I-upper_bound
day 50 53 840 843 I-upper_bound
within 54 60 844 850 O
6 61 62 851 852 B-upper_bound
months 63 69 853 859 I-upper_bound
of 70 72 860 862 O
study 73 78 863 868 O
entry 79 84 869 874 O

Cytoreduction 0 13 875 888 B-treatment
therapy 14 21 889 896 I-treatment
with 22 26 897 901 O
plasmapheresis 27 41 902 916 B-treatment
or 42 44 917 919 O
hydroxyurea 45 56 920 931 B-treatment
acceptable 57 67 932 942 O

Ejection 0 8 943 951 B-clinical_variable
fraction 9 17 952 960 I-clinical_variable
> 18 19 961 962 O
= 19 20 962 963 O
40 20 22 963 965 B-lower_bound
% 22 23 965 966 I-lower_bound
by 24 26 967 969 O
transthoracic 27 40 970 983 B-treatment
echocardiogram 41 55 984 998 I-treatment
or 56 58 999 1001 O
radionuclide 59 71 1002 1014 B-treatment
ventriculogram 72 86 1015 1029 I-treatment
, 86 87 1029 1030 O
i.e. 88 92 1031 1035 O
MUGA 93 97 1036 1040 B-treatment
scan 98 102 1041 1045 I-treatment

Females 0 7 1046 1053 B-gender
must 8 12 1054 1058 O
have 13 17 1059 1063 O
a 18 19 1064 1065 O
negative 20 28 1066 1074 B-pregnancy
serum 29 34 1075 1080 I-pregnancy
pregnancy 35 44 1081 1090 I-pregnancy
test 45 49 1091 1095 O
24 50 52 1096 1098 B-upper_bound
hours 53 58 1099 1104 I-upper_bound
prior 59 64 1105 1110 I-upper_bound
to 65 67 1111 1113 O
the 68 71 1114 1117 O
start 72 77 1118 1123 O
of 78 80 1124 1126 O
treatment 81 90 1127 1136 B-treatment
or 91 93 1137 1139 O
be 94 96 1140 1142 O
surgically 97 107 1143 1153 O
or 108 110 1154 1156 O
biologically 111 123 1157 1169 O
sterile 124 131 1170 1177 O
or 132 134 1178 1180 O
postmenopausal 135 149 1181 1195 O
( 150 151 1196 1197 O
amenorrheic 151 162 1197 1208 B-chronic_disease
for 163 166 1209 1212 O
at 167 169 1213 1215 O
least 170 175 1216 1221 O
12 176 178 1222 1224 B-upper_bound
months 179 185 1225 1231 I-upper_bound
) 185 186 1231 1232 O

First 0 5 1233 1238 O
relapse 6 13 1239 1246 O
within 14 20 1247 1253 O
12 21 23 1254 1256 B-upper_bound
months 24 30 1257 1263 I-upper_bound
after 31 36 1264 1269 I-upper_bound
date 37 41 1270 1274 O
of 42 44 1275 1277 O
first 45 50 1278 1283 O
CR 51 53 1284 1286 B-clinical_variable
or 54 56 1287 1289 I-clinical_variable
CRi 57 60 1290 1293 I-clinical_variable

Histologically 0 14 1294 1308 O
confirmed 15 24 1309 1318 O
AML 25 28 1319 1322 B-cancer
by 29 31 1323 1325 O
hematopathology 32 47 1326 1341 O
review 48 54 1342 1348 O
performed 55 64 1349 1358 O
within 65 71 1359 1365 O
four 72 76 1366 1370 B-upper_bound
weeks 77 82 1371 1376 I-upper_bound
prior 83 88 1377 1382 I-upper_bound
to 89 91 1383 1385 O
study 92 97 1386 1391 O
entry 98 103 1392 1397 O

Hypercellular 0 13 1398 1411 B-clinical_variable
bone 14 18 1412 1416 I-clinical_variable
marrow 19 25 1417 1423 I-clinical_variable
with 26 30 1424 1428 O
greater 31 38 1429 1436 O
than 39 43 1437 1441 O
20 44 46 1442 1444 B-lower_bound
% 46 47 1444 1445 I-lower_bound
cellularity 48 59 1446 1457 B-clinical_variable
and 60 63 1458 1461 O
10 64 66 1462 1464 O
% 66 67 1464 1465 O
blasts 68 74 1466 1472 O
at 75 77 1473 1475 O
least 78 83 1476 1481 O
14 84 86 1482 1484 B-lower_bound
days 87 91 1485 1489 I-lower_bound
after 92 97 1490 1495 O
first 98 103 1496 1501 O
induction 104 113 1502 1511 O
cycle 114 119 1512 1517 O
day 120 123 1518 1521 O
1 124 125 1522 1523 O

Known 0 5 1524 1529 O
active 6 12 1530 1536 O
HIV 13 16 1537 1540 B-chronic_disease
, 16 17 1540 1541 O
hepatitis 18 27 1542 1551 B-chronic_disease
B 28 29 1552 1553 I-chronic_disease
or 30 32 1554 1556 O
C 33 34 1557 1558 B-chronic_disease
or 35 37 1559 1561 O
infection 38 47 1562 1571 B-chronic_disease

Known 0 5 1572 1577 O
or 6 8 1578 1580 O
suspected 9 18 1581 1590 O
drug 19 23 1591 1595 O
sensitivity 24 35 1596 1607 O
to 36 38 1608 1610 O
cytarabine 39 49 1611 1621 B-allergy_name
or 50 52 1622 1624 O
the 53 56 1625 1628 O
investigational 57 72 1629 1644 O
agent 73 78 1645 1650 O
ficlatuzumab 79 91 1651 1663 B-allergy_name

More 0 4 1664 1668 O
than 5 9 1669 1673 O
2 10 11 1674 1675 B-lower_bound
cycles 12 18 1676 1682 O
of 19 21 1683 1685 O
prior 22 27 1686 1691 B-treatment
induction 28 37 1692 1701 I-treatment
therapy 38 45 1702 1709 I-treatment
for 46 49 1710 1713 O
AML 50 53 1714 1717 B-cancer

No 0 2 1718 1720 O
active 3 9 1721 1727 O
graft 10 15 1728 1733 B-chronic_disease
versus 16 22 1734 1740 I-chronic_disease
host 23 27 1741 1745 I-chronic_disease
disease 28 35 1746 1753 I-chronic_disease
( 36 37 1754 1755 I-chronic_disease
GVHD 37 41 1755 1759 I-chronic_disease
) 41 42 1759 1760 I-chronic_disease
or 43 45 1761 1763 O
immunosuppression 46 63 1764 1781 B-chronic_disease
for 64 67 1782 1785 O
prevention 68 78 1786 1796 O
or 79 81 1797 1799 O
treatment 82 91 1800 1809 B-treatment
of 92 94 1810 1812 O
GVHD 95 99 1813 1817 O
within 100 106 1818 1824 O
two 107 110 1825 1828 B-upper_bound
weeks 111 116 1829 1834 I-upper_bound
of 117 119 1835 1837 O
study 120 125 1838 1843 O
entry 126 131 1844 1849 O

Persistent 0 10 1850 1860 B-treatment
AML 11 14 1861 1864 I-treatment
documented 15 25 1865 1875 O
by 26 28 1876 1878 O
bone 29 33 1879 1883 B-treatment
marrow 34 40 1884 1890 I-treatment
biopsy 41 47 1891 1897 I-treatment
at 48 50 1898 1900 O
least 51 56 1901 1906 O
28 57 59 1907 1909 B-lower_bound
days 60 64 1910 1914 I-lower_bound
after 65 70 1915 1920 O
day 71 74 1921 1924 O
1 75 76 1925 1926 O
of 77 79 1927 1929 O
the 80 83 1930 1933 O
first 84 89 1934 1939 O
induction 90 99 1940 1949 O
cycle 100 105 1950 1955 O
of 106 108 1956 1958 O
cytotoxic 109 118 1959 1968 B-treatment
chemotherapy 119 131 1969 1981 I-treatment

Pregnant 0 8 1982 1990 B-pregnancy
women 9 14 1991 1996 B-gender
are 15 18 1997 2000 O
excluded 19 27 2001 2009 O
from 28 32 2010 2014 O
this 33 37 2015 2019 O
study 38 43 2020 2025 O
because 44 51 2026 2033 O
the 52 55 2034 2037 O
effect 56 62 2038 2044 O
of 63 65 2045 2047 O
ficlatuzumab 66 78 2048 2060 B-treatment
on 79 81 2061 2063 O
the 82 85 2064 2067 O
developing 86 96 2068 2078 O
fetus 97 102 2079 2084 O
remains 103 110 2085 2092 O
unknown 111 118 2093 2100 O
and 119 122 2101 2104 O
that 123 127 2105 2109 O
cytarabine 128 138 2110 2120 B-treatment
is 139 141 2121 2123 O
a 142 143 2124 2125 O
pregnancy 144 153 2126 2135 B-pregnancy
risk 154 158 2136 2140 O
category 159 167 2141 2149 O
D 168 169 2150 2151 O
drug 170 174 2152 2156 O
with 175 179 2157 2161 O
known 180 185 2162 2167 O
teratogenic 186 197 2168 2179 B-treatment
or 198 200 2180 2182 O
abortifacient 201 214 2183 2196 O
effects 215 222 2197 2204 O

Prior 0 5 2205 2210 O
exposure 6 14 2211 2219 O
to 15 17 2220 2222 O
the 18 21 2223 2226 O
investigational 22 37 2227 2242 B-treatment
agent 38 43 2243 2248 I-treatment
or 44 46 2249 2251 O
anti 47 51 2252 2256 B-treatment
- 51 52 2256 2257 I-treatment
c 52 53 2257 2258 I-treatment
- 53 54 2258 2259 I-treatment
Met 54 57 2259 2262 I-treatment
, 57 58 2262 2263 O
anti 59 63 2264 2268 B-treatment
- 63 64 2268 2269 I-treatment
HGF 64 67 2269 2272 I-treatment
or 68 70 2273 2275 O
anti 71 75 2276 2280 B-treatment
- 75 76 2280 2281 I-treatment
VEGF 76 80 2281 2285 I-treatment
directed 81 89 2286 2294 I-treatment
therapy 90 97 2295 2302 I-treatment
within 98 104 2303 2309 O
six 105 108 2310 2313 B-upper_bound
months 109 115 2314 2320 I-upper_bound
prior 116 121 2321 2326 I-upper_bound
to 122 124 2327 2329 O
study 125 130 2330 2335 O
entry 131 136 2336 2341 O

Prior 0 5 2342 2347 O
grade 6 11 2348 2353 O
4 12 13 2354 2355 O
toxicity 14 22 2356 2364 O
attributed 23 33 2365 2375 O
to 34 36 2376 2378 O
cytarabine 37 47 2379 2389 B-treatment

Prior 0 5 2390 2395 B-treatment
induction 6 15 2396 2405 I-treatment
therapy 16 23 2406 2413 I-treatment
had 24 27 2414 2417 O
to 28 30 2418 2420 O
include 31 38 2421 2428 O
no 39 41 2429 2431 O
more 42 46 2432 2436 O
than 47 51 2437 2441 O
two 52 55 2442 2445 B-lower_bound
cycles 56 62 2446 2452 O
of 63 65 2453 2455 O
cytotoxic 66 75 2456 2465 B-treatment
chemotherapy 76 88 2466 2478 I-treatment
and 89 92 2479 2482 O
at 93 95 2483 2485 O
least 96 101 2486 2491 O
one 102 105 2492 2495 B-lower_bound
induction 106 115 2496 2505 O
cycle 116 121 2506 2511 O
must 122 126 2512 2516 O
have 127 131 2517 2521 O
consisted 132 141 2522 2531 O
of 142 144 2532 2534 O
an 145 147 2535 2537 O
anthracycline 148 161 2538 2551 B-treatment
or 162 164 2552 2554 O
anthracenedione 165 180 2555 2570 B-treatment
and 181 184 2571 2574 O
cytarabine 185 195 2575 2585 B-treatment
combination 196 207 2586 2597 O
with 208 212 2598 2602 O
a 213 214 2603 2604 O
reasonable 215 225 2605 2615 O
schedule 226 234 2616 2624 O
/ 234 235 2624 2625 O
dose 235 239 2625 2629 O
according 240 249 2630 2639 O
to 250 252 2640 2642 O
the 253 256 2643 2646 O
discretion 257 267 2647 2657 O
of 268 270 2658 2660 O
the 271 274 2661 2664 O
investigator 275 287 2665 2677 O

Prior 0 5 2678 2683 B-treatment
treatment 6 15 2684 2693 I-treatment
of 16 18 2694 2696 O
myelodysplastic 19 34 2697 2712 B-cancer
syndrome 35 43 2713 2721 I-cancer
or 44 46 2722 2724 O
myeloproliferative 47 65 2725 2743 B-cancer
neoplasm 66 74 2744 2752 I-cancer
with 75 79 2753 2757 O
hypomethylating 80 95 2758 2773 B-treatment
agent 96 101 2774 2779 I-treatment
acceptable 102 112 2780 2790 O

The 0 3 2791 2794 O
effects 4 11 2795 2802 O
of 12 14 2803 2805 O
ficlatuzumab 15 27 2806 2818 B-treatment
on 28 30 2819 2821 O
the 31 34 2822 2825 O
developing 35 45 2826 2836 O
human 46 51 2837 2842 O
fetus 52 57 2843 2848 O
are 58 61 2849 2852 O
unknown 62 69 2853 2860 O

Transplantation 0 15 2861 2876 B-treatment
for 16 19 2877 2880 O
AML 20 23 2881 2884 B-cancer
( 24 25 2885 2886 O
allogeneic 25 35 2886 2896 O
or 36 38 2897 2899 O
autologous 39 49 2900 2910 O
) 49 50 2910 2911 O
allowed 51 58 2912 2919 O
unless 59 65 2920 2926 O
within 66 72 2927 2933 O
90 73 75 2934 2936 B-upper_bound
days 76 80 2937 2941 I-upper_bound
of 81 83 2942 2944 O
study 84 89 2945 2950 O
entry 90 95 2951 2956 O

Treatment 0 9 2957 2966 B-treatment
for 10 13 2967 2970 O
non 14 17 2971 2974 B-cancer
- 17 18 2974 2975 I-cancer
hematologic 18 29 2975 2986 I-cancer
malignancy 30 40 2987 2997 I-cancer
greater 41 48 2998 3005 O
than 49 53 3006 3010 O
6 54 55 3011 3012 B-lower_bound
months 56 62 3013 3019 I-lower_bound
prior 63 68 3020 3025 I-lower_bound
to 69 71 3026 3028 O
enrollment 72 82 3029 3039 O
is 83 85 3040 3042 O
acceptable 86 96 3043 3053 O

Uncontrolled 0 12 3054 3066 B-chronic_disease
infection 13 22 3067 3076 I-chronic_disease

Uncontrolled 0 12 3077 3089 O
intercurrent 13 25 3090 3102 O
illness 26 33 3103 3110 O
or 34 36 3111 3113 O
psychiatric 37 48 3114 3125 B-chronic_disease
illness 49 56 3126 3133 I-chronic_disease
/ 56 57 3133 3134 I-chronic_disease
social 57 63 3134 3140 I-chronic_disease
situations 64 74 3141 3151 I-chronic_disease
that 75 79 3152 3156 O
would 80 85 3157 3162 O
limit 86 91 3163 3168 O
compliance 92 102 3169 3179 O
with 103 107 3180 3184 O
study 108 113 3185 3190 O
requirements 114 126 3191 3203 O

patients 0 8 3204 3212 O
with 9 13 3213 3217 O
hepatitis 14 23 3218 3227 B-chronic_disease
B 24 25 3228 3229 I-chronic_disease
on 26 28 3230 3232 O
antivirals 29 39 3233 3243 O
and 40 43 3244 3247 O
low 44 47 3248 3251 O
viral 48 53 3252 3257 O
load 54 58 3258 3262 O

